These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38636974)

  • 21. "Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis." A. Campredon, E. Battistella, C. Martin,
    Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36997234
    [No Abstract]   [Full Text] [Related]  

  • 22. "Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis." Yael Gernez, Jeffrey Waters, Bojana Mirković, Gillian M. Lavelle, Colleen E. Dunn, Zoe A. Davies, Cassie Everson, Rabindra Tirouvanziam, Elana Silver, Sylvan Wallenstein, Sanjay H. Chotirmall, Noel G. McElvaney, Leonore A. Herzenberg and Richard B. Moss. Eur Respir J 2016; 47: 177-185.
    Eur Respir J; 2016 Jun; 47(6):1892. PubMed ID: 27246085
    [No Abstract]   [Full Text] [Related]  

  • 23. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders.
    Pagin A; Sermet-Gaudelus I; Burgel PR
    Arch Pediatr; 2020 Feb; 27 Suppl 1():eS25-eS29. PubMed ID: 32172933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CFTR gene mutations in adults with disseminated bronchiectasis.
    Girodon E; Cazeneuve C; Lebargy F; Chinet T; Costes B; Ghanem N; Martin J; Lemay S; Scheid P; Housset B; Bignon J; Goossens M
    Eur J Hum Genet; 1997; 5(3):149-55. PubMed ID: 9272738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.
    Paredes Aller S; Quittner AL; Salathe MA; Schmid A
    Expert Rev Respir Med; 2018 Sep; 12(9):769-782. PubMed ID: 30025482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and early life risk factors for bronchiectasis in cystic fibrosis: a review.
    Sly PD; Wainwright CE
    Expert Rev Respir Med; 2016 Sep; 10(9):1003-10. PubMed ID: 27329819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morbidity and mortality in carriers of the cystic fibrosis mutation
    Çolak Y; Nordestgaard BG; Afzal S
    Eur Respir J; 2020 Sep; 56(3):. PubMed ID: 32398304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The L441P mutation of cystic fibrosis transmembrane conductance regulator and its molecular pathogenic mechanisms in a Korean patient with cystic fibrosis.
    Gee HY; Kim CK; Kim SW; Lee JH; Kim JH; Kim KH; Lee MG
    J Korean Med Sci; 2010 Jan; 25(1):166-71. PubMed ID: 20052366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corneal Refractive Surgery Considerations in Patients with Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders.
    Moshirfar M; Brown AH; Sulit CA; Corbin WM; Ronquillo YC; Hoopes PC
    Int Med Case Rep J; 2022; 15():647-656. PubMed ID: 36388243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis.
    Bode SFN; Rapp H; Lienert N; Appel H; Fabricius D
    Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3271-3277. PubMed ID: 36738326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and genetic analysis of cystic fibrosis transmembrane conductance reseptor-related disease.
    Kilinc AA; Alishbayli G; Taner HE; Cokugras FC; Cokugras H
    Pediatr Int; 2020 May; 62(5):629-633. PubMed ID: 32003094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging medicines to improve the basic defect in cystic fibrosis.
    Fajac I; Sermet-Gaudelus I
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation.
    Wielpütz MO; Eichinger M; Biederer J; Wege S; Stahl M; Sommerburg O; Mall MA; Kauczor HU; Puderbach M
    Rofo; 2016 Sep; 188(9):834-45. PubMed ID: 27074425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry." Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Christopher Zappala, Heather Allan, Gregory J. Keir, Andrew Hayen, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Sacha Macansh and Tamera J. Corte.
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356377
    [No Abstract]   [Full Text] [Related]  

  • 37. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches.
    Graeber SY; Mall MA
    Lancet; 2023 Sep; 402(10408):1185-1198. PubMed ID: 37699417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the Disease-Liability of Mutations in CFTR.
    Ferec C; Cutting GR
    Cold Spring Harb Perspect Med; 2012 Dec; 2(12):a009480. PubMed ID: 23209179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His.
    Keenan K; Dupuis A; Griffin K; Castellani C; Tullis E; Gonska T
    J Cyst Fibros; 2019 Mar; 18(2):265-270. PubMed ID: 30279124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disrupted post-transcriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by a 5'UTR mutation is associated with a CFTR-related disease.
    Lukowski SW; Bombieri C; Trezise AE
    Hum Mutat; 2011 Oct; 32(10):E2266-82. PubMed ID: 21837768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.